Cargando…

In vitro Antitumor Activity of TAS‐103, a Novel Quinoline Derivative That Targets Topoisomerases I and II

TAS‐103 is a novel anticancer agent targeting both topoisomerase (Topo) I and Topo II, that stabilizes cleavable complexes of Topo‐DNA at the cellular level. In this study, the in vitro antitumor effects of TAS‐103 were compared with those of other known Topo I and Topo II inhibitors. TAS‐103 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aoyagi, Yoshimi, Kobunai, Takashi, Utsugi, Teruhiro, Oh‐hara, Tomoko, Yamada, Yuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1999
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926096/ https://www.ncbi.nlm.nih.gov/pubmed/10391099 http://dx.doi.org/10.1111/j.1349-7006.1999.tb00786.x

Ejemplares similares

Antitumor Activity of a Novel Quinoline Derivative, TAS‐103, with Inhibitory Effects on Topoisomerases I and II
por: Utsugi, Teruhiro, et al.
Publicado: (1997)

Establishment and Characterization of 6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐c]quinolin‐7‐one dihydrochloride (TAS‐103)‐resistant Cell Lines
por: Aoyagi, Yoshimi, et al.
Publicado: (2000)

A Dual Topoisomerase Inhibitor, TAS‐103, Induces Apoptosis in Human Cancer Cells
por: Ohyama, Tomoko, et al.
Publicado: (1999)

Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
por: Suzuki, Rikio, et al.
Publicado: (2014)

Inhibition of Topoisomerase II by a Novel Antitumor Cyclic Depsipeptide, BE‐22179
por: Yoshinari, Tomoko, et al.
Publicado: (1994)

TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice
por: Tanaka, Yuki, et al.
Publicado: (2020)

Author Correction: TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice
por: Tanaka, Yuki, et al.
Publicado: (2022)

New Challenges and Inspired Answers for Anticancer Drug Discovery and Development
por: Utsugi, Teruhiro
Publicado: (2013)

Design, Synthesis, and Cytotoxicity and Topoisomerase I/IIα Inhibition Activity of Pyrazolo[4,3-f]quinoline Derivatives
por: Chaudhary, Chhabi Lal, et al.
Publicado: (2022)

A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA Complex
por: Hanada, Mitsuharu, et al.
Publicado: (1998)

Identification and Characterization of a Deletion Mutant of DNA Topoisomerase I mRNA in a Camptothecin‐resistant Subline of Human Colon Carcinoma
por: Yanase, Kae, et al.
Publicado: (2000)

Antitumor Activity and Pharmacokinetics of TAS‐106, l‐(3‐C‐Ethynyl‐β‐D‐ribo‐pentofuranosyl)cytosine
por: Shimamoto, Yuji, et al.
Publicado: (2001)

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997)

Identification of Novel 4′-O-Demethyl-epipodophyllotoxin Derivatives as Antitumor Agents Targeting Topoisomerase II
por: Xi, Wenli, et al.
Publicado: (2022)

Eribulin mesylate exerts antitumor effects via CD103
por: Oya, Kazumasa, et al.
Publicado: (2023)

IND-2, a Quinoline Derivative, Inhibits the Proliferation of Prostate Cancer Cells by Inducing Oxidative Stress, Apoptosis and Inhibiting Topoisomerase II
por: Balaji, Swapnaa, et al.
Publicado: (2022)

Shieldings: TAS
Publicado: (2004)

Shieldings: TAS
Publicado: (2004)

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
por: TANAKA, NOZOMU, et al.
Publicado: (2014)

Biomodulation by Hyperthermia of Topoisomerase II‐Targeting Drugs in Human Colorectal Cancer Cells
por: Hirohashi, Yoshimi, et al.
Publicado: (1995)

MSN8C: A Promising Candidate for Antitumor Applications as a Novel Catalytic Inhibitor of Topoisomerase II
por: Ou, Jie-Bin, et al.
Publicado: (2023)

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint
por: Kozuki, Toshiyuki, et al.
Publicado: (2017)

TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress
por: Ueno, Hiroyuki, et al.
Publicado: (2022)

A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study)
por: Yoshida, Yoichiro, et al.
Publicado: (2019)

Advances in antitumor research of CA-4 analogs carrying quinoline scaffold
por: Wang, Chao, et al.
Publicado: (2022)

Vanillin Activates Human Bitter Taste Receptors TAS2R14, TAS2R20, and TAS2R39
por: Morini, Gabriella, et al.
Publicado: (2021)

Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II
por: Molinaro, Caroline, et al.
Publicado: (2020)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

Localization of topoisomerase II in mitotic chromosomes
Publicado: (1985)

Topoisomerase II has to work late
por: Leslie, Mitch
Publicado: (2014)

Diversity and Functions of Type II Topoisomerases
por: Sutormin, D. A., et al.
Publicado: (2021)

Chromatinization Modulates Topoisomerase II Processivity
por: Lee, Jaeyoon, et al.
Publicado: (2023)

Chromatinization modulates topoisomerase II processivity
por: Lee, Jaeyoon, et al.
Publicado: (2023)

Natural Products as Topoisomerase II Poisons: Effects of Thymoquinone on DNA Cleavage Mediated by Human Topoisomerase IIα
por: Ashley, Rachel E., et al.
Publicado: (2014)

Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II
por: Xu, Huanli, et al.
Publicado: (2016)

Tas chebal : jun chajp a'tel pajbil /
por: González Dillon, Mónica
Publicado: (2013)

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors
por: Miura, Yosuke, et al.
Publicado: (2017)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a(-/- )mutants
por: Sapetto-Rebow, Beata, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ssski7o7ec6q17dncovpdr3adf